Squamous Cell Carcinoma

Curated

← investigated for

Retifanlimabmonoclonal_antibody

unknown

Curated

← investigated for

Pembrolizumabmonoclonal_antibody

unknown

Curated

← investigated for

Hydroxyureasmall_molecule

unknown

Curated

← investigated for

Hydroxycarbamidesmall_molecule

unknown

Curated

← investigated for

Cetuximabmonoclonal_antibody

unknown

Curated

← investigated for

Cemiplimabmonoclonal_antibody

unknown

Curated

← investigated for

Bleomycin

unknown

Curated

← investigated for

Vinorelbinesmall_molecule

unknown

Curated

← investigated for

Tretinoinsmall_molecule

unknown

Curated

← investigated for

Tremelimumabmonoclonal_antibody

unknown

Curated

← investigated for

Topotecansmall_molecule

unknown

Curated

← investigated for

Raltitrexedsmall_molecule

unknown

Curated

← investigated for

Panitumumabmonoclonal_antibody

unknown

Curated

← investigated for

Palbociclibsmall_molecule

unknown

Curated

← investigated for

Paclitaxelsmall_molecule

unknown

Curated

← investigated for

Oxaliplatinsmall_molecule

unknown

Curated

← investigated for

Nivolumabmonoclonal_antibody

unknown

Curated

← investigated for

Nimotuzumabmonoclonal_antibody

unknown

Curated

← investigated for

Nedaplatinsmall_molecule

unknown

Curated

← investigated for

Methotrexatesmall_molecule

unknown

Curated

← investigated for

Lenvatinibsmall_molecule

unknown

Curated

← investigated for

Ipilimumabmonoclonal_antibody

unknown

Curated

← investigated for

Iniparibsmall_molecule

unknown

Curated

← investigated for

Gemcitabinesmall_molecule

unknown

Curated

← investigated for

Gefitinibsmall_molecule

unknown

Curated

← investigated for

Fluorouracilsmall_molecule

unknown

Curated

← investigated for

Etoposidesmall_molecule

unknown

Curated

← investigated for

Erlotinib Hydrochloridesmall_molecule

unknown

Curated

← investigated for

Erlotinibsmall_molecule

unknown

Curated

← investigated for

Durvalumabmonoclonal_antibody

unknown

Curated

← investigated for

Docetaxelsmall_molecule

unknown

Curated

← investigated for

Cyclophosphamidesmall_molecule

unknown

Curated

← investigated for

Cisplatinsmall_molecule

unknown

Curated

← investigated for

Carboplatinsmall_molecule

unknown

Curated

← investigated for

Capecitabinesmall_molecule

unknown

Curated

← investigated for

Camrelizumabmonoclonal_antibody

unknown

Curated

← investigated for

Avelumabmonoclonal_antibody

unknown

Curated

← investigated for

Atezolizumabmonoclonal_antibody

unknown

Curated

← investigated for

Aspirinsmall_molecule

unknown

Curated

← investigated for

Afatinibsmall_molecule

unknown

Curated

← investigated for

Vistusertibsmall_molecule

unknown

Curated

← investigated for

Vandetanibsmall_molecule

unknown

Curated

← investigated for

Valproic Acidsmall_molecule

unknown

Curated

← investigated for

Treosulfansmall_molecule

unknown

Curated

← investigated for

Toripalimabmonoclonal_antibody

unknown

Curated

← investigated for

Tislelizumabmonoclonal_antibody

unknown

Curated

← investigated for

Tipifarnibsmall_molecule

unknown

Curated

← investigated for

Temsirolimussmall_molecule

unknown

Curated

← investigated for

Tegafursmall_molecule

unknown

Curated

← investigated for

Taselisibsmall_molecule

unknown

Curated

← investigated for

Tarloxotinibsmall_molecule

unknown

Curated

← investigated for

Talazoparibsmall_molecule

unknown

Curated

← investigated for

Sunitinibsmall_molecule

unknown

Curated

← investigated for

Sulindacsmall_molecule

unknown

Curated

← investigated for

Sintilimabmonoclonal_antibody

unknown

Curated

← investigated for

Serplulimabmonoclonal_antibody

unknown

Curated

← investigated for

Selumetinibsmall_molecule

unknown

Curated

← investigated for

Selinexorsmall_molecule

unknown

Curated

← investigated for

Sapanisertibsmall_molecule

unknown

Curated

← investigated for

Ruxolitinibsmall_molecule

unknown

Curated

← investigated for

Rilotumumabmonoclonal_antibody

unknown

Curated

← investigated for

Rigosertibsmall_molecule

unknown

Curated

← investigated for

Ramucirumabmonoclonal_antibody

unknown

Curated

← investigated for

Pemetrexedsmall_molecule

unknown

Curated

← investigated for

Peginterferon Alfa-2bother

unknown

Curated

← investigated for

Pegfilgrastimother

unknown

Curated

← investigated for

Pazopanibsmall_molecule

unknown

Curated

← investigated for

Osimertinib Mesylatesmall_molecule

unknown

Curated

← investigated for

Osimertinibsmall_molecule

unknown

Curated

← investigated for

Olaparibsmall_molecule

unknown

Curated

← investigated for

Niraparibsmall_molecule

unknown

Curated

← investigated for

Nintedanibsmall_molecule

unknown

Curated

← investigated for

Niacinamidesmall_molecule

unknown

Curated

← investigated for

Necitumumabmonoclonal_antibody

unknown

Curated

← investigated for

Mitomycinsmall_molecule

unknown

Curated

← investigated for

Metforminsmall_molecule

unknown

Curated

← investigated for

Lifileucelcell_therapy

unknown

Curated

← investigated for

Lenalidomidesmall_molecule

unknown

Curated

← investigated for

Lapatinibsmall_molecule

unknown

Curated

← investigated for

Irinotecansmall_molecule

unknown

Curated

← investigated for

Infigratinibsmall_molecule

unknown

Curated

← investigated for

Icotinibsmall_molecule

unknown

Curated

← investigated for

Ibrutinibsmall_molecule

unknown

Curated

← investigated for

Filgrastimother

unknown

Curated

← investigated for

Fexagratinibsmall_molecule

unknown

Curated

← investigated for

Everolimussmall_molecule

unknown

Curated

← investigated for

Erdafitinibsmall_molecule

unknown

Curated

← investigated for

Duvelisibsmall_molecule

unknown

Curated

← investigated for

Dexamethasonesmall_molecule

unknown

Curated

← investigated for

Dasatinibsmall_molecule

unknown

Curated

← investigated for

Dacomitinibsmall_molecule

unknown

Curated

← investigated for

Dacomitinibsmall_molecule

unknown

Curated

← investigated for

Crizotinibsmall_molecule

unknown

Curated

← investigated for

Cixutumumabmonoclonal_antibody

unknown

Curated

← investigated for

Capivasertibsmall_molecule

unknown

Curated

← investigated for

Cabazitaxelsmall_molecule

unknown

Curated

← investigated for

Buparlisibsmall_molecule

unknown

Curated

← investigated for

Bimiralisibsmall_molecule

unknown

Curated

← investigated for

Bevacizumabmonoclonal_antibody

unknown

Curated

← investigated for

Axitinibsmall_molecule

unknown

Curated

← investigated for

Aumolertinibsmall_molecule

unknown

Curated

← investigated for

Alpelisibsmall_molecule

unknown

Curated

← investigated for

Adebrelimabmonoclonal_antibody

unknown

Curated

← investigated for

Acalabrutinibsmall_molecule

unknown

Curated

← investigated for

Abemaciclibsmall_molecule

unknown

Curated

← investigated for

Vorinostatsmall_molecule

unknown

Curated

← investigated for

Veliparibsmall_molecule

unknown

Curated

← investigated for

Tazemetostatsmall_molecule

unknown

Curated

← investigated for

Sorafenib Tosylatesmall_molecule

unknown

Curated

← investigated for

Sorafenibsmall_molecule

unknown

Curated

← investigated for

Sirolimussmall_molecule

unknown

Curated

← investigated for

Rituximabmonoclonal_antibody

unknown

Curated

← investigated for

Ribociclibsmall_molecule

unknown

Curated

← investigated for

Prexasertibsmall_molecule

unknown

Curated

← investigated for

Patritumabmonoclonal_antibody

unknown

Curated

← investigated for

Methyl Aminolevulinatesmall_molecule

unknown

Curated

← investigated for

Luminespibsmall_molecule

unknown

Curated

← investigated for

Linsitinibsmall_molecule

unknown

Curated

← investigated for

Leucovorinsmall_molecule

unknown

Curated

← investigated for

Imiquimodsmall_molecule

unknown

Curated

← investigated for

Fulvestrantsmall_molecule

unknown

Curated

← investigated for

Fludarabinesmall_molecule

unknown

Curated

← investigated for

Dostarlimabmonoclonal_antibody

unknown

Curated

← investigated for

Decitabinesmall_molecule

unknown

Curated

← investigated for

Copanlisibsmall_molecule

unknown

Curated

← investigated for

Cabozantinibsmall_molecule

unknown

Curated

← investigated for

Bortezomibsmall_molecule

unknown

Curated

← investigated for

Berzosertibsmall_molecule

unknown

Curated

← investigated for

Azacitidinesmall_molecule

unknown

Curated

← investigated for

Amivantamabmonoclonal_antibody

unknown

Curated

← investigated for

Alisertibsmall_molecule

unknown

Curated

← investigated for

Aldesleukinother

unknown

Curated

← investigated for

Adavosertibsmall_molecule

unknown

Curated

← investigated for

Imatinib Mesylatesmall_molecule

unknown

0.5

Curated

← investigated for

Imatinibsmall_molecule

unknown

0.5

Curated

Skin Squamous Cell Carcinoma

Squamous Cell Carcinoma altered in cohorts of …ALTERED_INderived15 of 474show all (up to 200)
← altered in cohorts of	MUC12 24 / 25 cases (96 %) · ssm · cscc_ranson_2022	—	—	Skin Squamous Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	ABCC5 444 / 504 cases (88 %) · ssm · TCGA-LUSC	—	—	Lung Squamous Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CCDC39 444 / 504 cases (88 %) · ssm · TCGA-LUSC	—	—	Lung Squamous Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	DVL3 444 / 504 cases (88 %) · ssm · TCGA-LUSC	—	—	Lung Squamous Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	EEF1AKMT4-ECE2 444 / 504 cases (88 %) · ssm · TCGA-LUSC	—	—	Lung Squamous Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	EPHB3 444 / 504 cases (88 %) · ssm · TCGA-LUSC	—	—	Lung Squamous Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	KLHL6 444 / 504 cases (88 %) · ssm · TCGA-LUSC	—	—	Lung Squamous Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	WDFY4 22 / 25 cases (88 %) · ssm · cscc_ranson_2022	—	—	Skin Squamous Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	ABCF3 443 / 504 cases (88 %) · ssm · TCGA-LUSC	—	—	Lung Squamous Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ACTRT3 443 / 504 cases (88 %) · ssm · TCGA-LUSC	—	—	Lung Squamous Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CHRD 443 / 504 cases (88 %) · ssm · TCGA-LUSC	—	—	Lung Squamous Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CLCN2 443 / 504 cases (88 %) · ssm · TCGA-LUSC	—	—	Lung Squamous Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	DCUN1D1 443 / 504 cases (88 %) · ssm · TCGA-LUSC	—	—	Lung Squamous Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	EIF2B5 443 / 504 cases (88 %) · ssm · TCGA-LUSC	—	—	Lung Squamous Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	HTR3C 443 / 504 cases (88 %) · ssm · TCGA-LUSC	—	—	Lung Squamous Cell Carcinoma	1	Observed	gdc	graph →

Squamous Cell Carcinoma altered in cohorts of …ALTERED_INderived15 of 474show all (up to 200)

← altered in cohorts of

MUC12

24 / 25 cases (96 %) · ssm · cscc_ranson_2022

—

Observed

cbioportal

← altered in cohorts of

ABCC5

444 / 504 cases (88 %) · ssm · TCGA-LUSC

—

Observed

← altered in cohorts of

CCDC39

444 / 504 cases (88 %) · ssm · TCGA-LUSC

—

Observed

← altered in cohorts of

DVL3

444 / 504 cases (88 %) · ssm · TCGA-LUSC

—

Observed

← altered in cohorts of

EEF1AKMT4-ECE2

444 / 504 cases (88 %) · ssm · TCGA-LUSC

—

Observed

← altered in cohorts of

EPHB3

444 / 504 cases (88 %) · ssm · TCGA-LUSC

—

Observed

← altered in cohorts of

KLHL6

444 / 504 cases (88 %) · ssm · TCGA-LUSC

—

Observed

Skin Squamous Cell Carcinoma

← altered in cohorts of

WDFY4

22 / 25 cases (88 %) · ssm · cscc_ranson_2022

—

Observed

cbioportal

← altered in cohorts of

ABCF3

443 / 504 cases (88 %) · ssm · TCGA-LUSC

—

Observed

← altered in cohorts of

ACTRT3

443 / 504 cases (88 %) · ssm · TCGA-LUSC

—

Observed

← altered in cohorts of

CHRD

443 / 504 cases (88 %) · ssm · TCGA-LUSC

—

Observed

← altered in cohorts of

CLCN2

443 / 504 cases (88 %) · ssm · TCGA-LUSC

—

Observed

← altered in cohorts of

DCUN1D1

443 / 504 cases (88 %) · ssm · TCGA-LUSC

—

Observed

← altered in cohorts of

EIF2B5

443 / 504 cases (88 %) · ssm · TCGA-LUSC

—

Observed

← altered in cohorts of

HTR3C

443 / 504 cases (88 %) · ssm · TCGA-LUSC

—

Observed

Squamous Cell Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 198show all (up to 200)
→ investigated in trials for	Cisplatinsmall_molecule 299 trials (103 active) · roll-up of the cancer and its descendants	—	—	Squamous Cell Carcinoma	299	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal_antibody 241 trials (115 active) · roll-up of the cancer and its descendants	—	—	Squamous Cell Carcinoma	241	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall_molecule 152 trials (61 active) · roll-up of the cancer and its descendants	—	—	Squamous Cell Carcinoma	152	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall_molecule 148 trials (68 active) · roll-up of the cancer and its descendants	—	—	Squamous Cell Carcinoma	148	Observed	clinicaltrials	graph →
→ investigated in trials for	Cetuximabmonoclonal_antibody 142 trials (35 active) · roll-up of the cancer and its descendants	—	—	Squamous Cell Carcinoma	142	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall_molecule 114 trials (35 active) · roll-up of the cancer and its descendants	—	—	Squamous Cell Carcinoma	114	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal_antibody 102 trials (41 active) · roll-up of the cancer and its descendants	—	—	Squamous Cell Carcinoma	102	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall_molecule 96 trials (30 active) · roll-up of the cancer and its descendants	—	—	Squamous Cell Carcinoma	96	Observed	clinicaltrials	graph →
→ investigated in trials for	Nab-paclitaxel 49 trials (24 active) · roll-up of the cancer and its descendants	—	—	Squamous Cell Carcinoma	49	Observed	clinicaltrials	graph →
→ investigated in trials for	Tislelizumabmonoclonal_antibody 48 trials (29 active) · roll-up of the cancer and its descendants	—	—	Squamous Cell Carcinoma	48	Observed	clinicaltrials	graph →
→ investigated in trials for	Cemiplimabmonoclonal_antibody 46 trials (27 active) · roll-up of the cancer and its descendants	—	—	Squamous Cell Carcinoma	46	Observed	clinicaltrials	graph →
→ investigated in trials for	Toripalimabmonoclonal_antibody 41 trials (23 active) · roll-up of the cancer and its descendants	—	—	Squamous Cell Carcinoma	41	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal_antibody 37 trials (4 active) · roll-up of the cancer and its descendants	—	—	Squamous Cell Carcinoma	37	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall_molecule 32 trials (8 active) · roll-up of the cancer and its descendants	—	—	Squamous Cell Carcinoma	32	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal_antibody 30 trials (10 active) · roll-up of the cancer and its descendants	—	—	Squamous Cell Carcinoma	30	Observed	clinicaltrials	graph →

Squamous Cell Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 198show all (up to 200)

→ investigated in trials for

Cisplatinsmall_molecule

299 trials (103 active) · roll-up of the cancer and its descendants

—

299

Observed

→ investigated in trials for

Pembrolizumabmonoclonal_antibody

241 trials (115 active) · roll-up of the cancer and its descendants

—

241

Observed

→ investigated in trials for

Paclitaxelsmall_molecule

152 trials (61 active) · roll-up of the cancer and its descendants

—

152

Observed

→ investigated in trials for

Carboplatinsmall_molecule

148 trials (68 active) · roll-up of the cancer and its descendants

—

148

Observed

→ investigated in trials for

Cetuximabmonoclonal_antibody

142 trials (35 active) · roll-up of the cancer and its descendants

—

142

Observed

→ investigated in trials for

Docetaxelsmall_molecule

114 trials (35 active) · roll-up of the cancer and its descendants

—

114

Observed

→ investigated in trials for

Nivolumabmonoclonal_antibody

102 trials (41 active) · roll-up of the cancer and its descendants

—

102

Observed

→ investigated in trials for

Fluorouracilsmall_molecule

96 trials (30 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nab-paclitaxel

49 trials (24 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tislelizumabmonoclonal_antibody

48 trials (29 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cemiplimabmonoclonal_antibody

46 trials (27 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Toripalimabmonoclonal_antibody

41 trials (23 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Durvalumabmonoclonal_antibody

37 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Capecitabinesmall_molecule

32 trials (8 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bevacizumabmonoclonal_antibody

30 trials (10 active) · roll-up of the cancer and its descendants

—

Observed

Bladder Squamous Cell Carcinoma

Squamous Cell Carcinoma studied in …STUDIED_INderived10 of 2,930show all (up to 200)
→ studied in	NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 2,930 trials mapped (1,119 active)	—	—	Bladder Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04267848Phase 3 · recruiting Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) · condition mapped ONTOLOGY_EXACT · 2,930 trials mapped (1,119 active)	—	—	Lung Non-Small Cell Squamous Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05057247Phase 2 · completed Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC · condition mapped ALIAS · 2,930 trials mapped (1,119 active)	—	—	Head and Neck Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05877599Phase 1 · recruiting A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation · condition mapped ONTOLOGY_EXACT · 2,930 trials mapped (1,119 active)	—	—	Head and Neck Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05891171Phase 1 · active not recruiting Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers · condition mapped ONTOLOGY_EXACT · 2,930 trials mapped (1,119 active)	—	—	Head and Neck Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06589804Phase 3 · recruiting Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment · condition mapped CURATED_BROADER · 2,930 trials mapped (1,119 active)	—	—	Head and Neck Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07061977Phase 3 · recruiting Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer · condition mapped CURATED_BROADER · 2,930 trials mapped (1,119 active)	—	—	Cervical Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07667400Phase 1/Phase 2 · not yet recruiting Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer · condition mapped ONTOLOGY_EXACT · 2,930 trials mapped (1,119 active)	—	—	Head and Neck Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07744126Phase 2 · recruiting A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 2,930 trials mapped (1,119 active)	—	—	Head and Neck Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07847060NA · not yet recruiting Hypofractionated Radiotherapy in Older Adults With Head and Neck Squamous Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 2,930 trials mapped (1,119 active)	—	—	Head and Neck Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →

Squamous Cell Carcinoma studied in …STUDIED_INderived10 of 2,930show all (up to 200)

→ studied in

NCT03866382Phase 2 · recruiting

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 2,930 trials mapped (1,119 active)

—

Observed

Lung Non-Small Cell Squamous Carcinoma

→ studied in

NCT04267848Phase 3 · recruiting

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) · condition mapped ONTOLOGY_EXACT · 2,930 trials mapped (1,119 active)

—

Observed

→ studied in

NCT05057247Phase 2 · completed

Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC · condition mapped ALIAS · 2,930 trials mapped (1,119 active)

—

Observed

→ studied in

NCT05877599Phase 1 · recruiting

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation · condition mapped ONTOLOGY_EXACT · 2,930 trials mapped (1,119 active)

—

Observed

→ studied in

NCT05891171Phase 1 · active not recruiting

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers · condition mapped ONTOLOGY_EXACT · 2,930 trials mapped (1,119 active)

—

Observed

→ studied in

NCT06589804Phase 3 · recruiting

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment · condition mapped CURATED_BROADER · 2,930 trials mapped (1,119 active)

—

Observed

Cervical Squamous Cell Carcinoma

→ studied in

NCT07061977Phase 3 · recruiting

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer · condition mapped CURATED_BROADER · 2,930 trials mapped (1,119 active)

—

Observed

→ studied in

NCT07667400Phase 1/Phase 2 · not yet recruiting

Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer · condition mapped ONTOLOGY_EXACT · 2,930 trials mapped (1,119 active)

—

Observed

→ studied in

NCT07744126Phase 2 · recruiting

A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 2,930 trials mapped (1,119 active)

—

Observed

→ studied in

NCT07847060NA · not yet recruiting

Hypofractionated Radiotherapy in Older Adults With Head and Neck Squamous Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 2,930 trials mapped (1,119 active)

—

Observed